CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$2.42 USD
+0.12 (5.22%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.43 +0.01 (0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth NA Momentum NA VGM
Price, Consensus and EPS Surprise
CASI 2.42 +0.12(5.22%)
Will CASI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CASI
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Other News for CASI
CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS
Casi Pharmaceuticals discloses development relating to dispute with Juventas
CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
Recap: CASI Pharmaceuticals Q4 Earnings
CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS